XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (2,245,720) $ 4,992,427
Adjustments to reconcile net loss to net cash used in operating activities    
Bad debt recovery (20,000) (83,500)
Stock-based compensation and professional fees 95,925 83,728
Amortization of prepaid stock-based professional fees 107,970
Net realized loss (gain) on equity investments 104,700 (6,655,120)
Net unrealized loss (gain) loss on equity investments 256,382 (369,626)
Equity shares earned for lock up agreement (85,733)
Gain on forgiveness of PPP note payable and accrued interest (19,082)
Gain from disposal of assets from discontinued operations   (1,553)
Change in operating assets and liabilities:    
Prepaid expenses and other current assets (481,675) (115,587)
Assets of discontinued operations (24,963)
Interest receivable (3,590)
Accounts payable and accrued expenses (194,292) 84,399
Insurance payable 16,447
Deferred revenue (54,077) 496,762
NET CASH USED IN OPERATING ACTIVITIES (2,611,633) (1,504,145)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Net proceeds from sale of equity investments 66,707 6,736,070
Collection on note receivable written off prior to 2019 7,500
Collection on note receivable 20,000 99,500
NET CASH PROVIDED BY INVESTING ACTIVITIES 86,707 6,843,070
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from sale of preferred stock 3,794,102
Net proceeds from sale of common stock 4,940,948
Advance from a related party 2,366
Repayment of advance from a related party (2,366)
NET CASH PROVIDED BY FINANCING ACTIVITIES 4,940,948 3,794,102
NET CHANGE IN CASH AND CASH EQUIVALENTS: 2,416,022 9,133,027
CASH AND CASH EQUIVALENTS - beginning of the period 9,837,001 1,128,389
CASH AND CASH EQUIVALENTS - end of the period 12,253,023 10,261,416
Cash paid during the period for:    
Interest 2,079
Income taxes 25,159
Non-cash investing and financing activities:    
Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement 531,250
Note receivable issued in connection with asset purchase agreement $ 60,000